Deferred Urgency Carotid Artery Stenting in Symptomatic Patients: Clinical Lessons and Biomarker Patterns from a Prospective Registry  by Setacci, C. et al.
Selected Abstracts from the June Issue of the
European Journal of Vascular and Endovascular Surgery
Piergiorgio Cao, MD, FRCS, Editor-in-Chief, and Jean-Baptiste Ricco, MD, PhD, Senior Editor
Deferred Urgency Carotid Artery Stenting in Symptomatic Patients:
Clinical Lessons and Biomarker Patterns from a Prospective Registry
Setacci C., de Donato G., Chisci E., Setacci F., Stella A., Faggioli G.,
Reimers B., Cernetti C., Lopera Quijada M.J., Cappi B., Sangiorgi G., on
behalf of the Submarine Registry Group. Eur J Vasc Endovasc Surg 2008;
35:644-51.
Introduction: The aim of this prospective observational registry was
to study the outcome of symptomatic patients presenting with recent
TIA or minor stroke and severe carotid stenosis, submitted to early
percutaneous treatment by stenting. A secondary aim was to evaluate the
biological activity of the symptomatic carotid plaques by serial serum and
urinary markers (PAPP-A, hs-CRP, MMP-2/MMP-9, IL-6/IL-8, TNF
alpha, CD40L) measured by enzyme-linked immunosorbent assay before
and after treatment.
Methods: FromMay 2005 to June 2006, 57 patients were enrolled in
this prospective registry. All patients underwent carotid stenting using a
concentric filter for cerebral protection. The procedure was performed
within 24–48 hrs of the last attack in patients with TIA (n  24, 42%) and
between 14 and 30 days in patients with stroke (n  33, 58%).
Results: Successful stent implantation was achieved in all cases (100%).
Adverse events at 1 month were 1 death (1.7%) and 2 TIAs (3.5%). Some of
the vulnerability markers, in particular those reflecting an active systemic
inflammatory process of the plaque (PAPP-A, hs-CR, and IL-6), were
significantly elevated at the time of enrolment, increased after stenting and
decreased after 30 days.
Conclusion:Deferred CAS is feasible and safe in selected patients with
symptomatic carotid stenosis. This preliminary study in a limited series of
patients with unstable carotid plaques revealed that endovascular treatment
has a satisfactory outcome considering the very high risk profile of the
patient population. The evaluation of some biomarkers suggested an inflam-
matory role in the process of an unstable carotid plaque generating an acute
cerebral event.
Peroperative Neuromonitoring during Carotid Endarterectomy in Re-
lation to Preoperative Positron Emission Tomography Findings
Rijbroek A., Boellaard R., Vriens E.M., Lammertsma A.A., Rauwerda J.A.
Eur J Vasc Endovasc Surg 2008;35:652-60.
Objectives: To compare stump pressure (SP), transcranial Doppler
(TCD), electroencephalography (EEG) and selective shunting during ca-
rotid endarterectomy (CEA) with preoperative positron emission tomogra-
phy (PET) parameters.
Materials and methods: Preoperative PET measurements and preop-
erative neuromonitoring were performed in ten patients undergoing CEA
for symptomatic carotid artery disease. PET parameters measured were
cerebral blood flow (CBF), oxygen extraction fraction (OEF), cerebral
oxygen metabolism (CMRO2), cerebral blood volume (CBV), mean vascu-
lar transit time (MVTT) and cerebral perfusion pressure (CPP). Results of
these measurements in ipsilateral medial cerebral artery (MCA), ipsilateral
hemisphere and total cerebrum were compared with absolute mean SP,
mean SP  40 mmHg, TCD, EEG changes and selective shunting.
Results: None of the PET parameters showed any significant correla-
tions with peroperative neuromonitoring findings. There were only trends
for correlations of CBF and MVTT with TCD changes and of CPP and
CMRO2 with selective shunting.
Conclusions: Preoperative PET examinations are not usefull for pre-
dicting the need for shunting during CEA.
Selective Screening for Abdominal Aortic Aneurysm among Patients
Referred to the Vascular Laboratory
ÅlundM., Mani K., Wanhainen A. Eur J Vasc Endovasc Surg 2008;35:669-
74.
Background: Patients examined for peripheral arterial disease at the
vascular laboratory, Uppsala University Hospital, are since 1993 screened
for abdominal aortic aneurysm (AAA). The objective of this study was to
study the prevalence of AAA found at this selective high-risk screening.
Methods: All files in the vascular laboratory were retrospectively re-
viewed. Of 9296 persons examined with arterial duplex between 1993 and
October 2005, 5924 were screened for AAA. The primary target vessel was
the carotid arteries in 3772 subjects, the renal arteries in 1529 subjects and
the lower extremity arteries in 1457 subjects. An AAA was defined as an
infrarenal aortic diameter 30 mm.
Results: 179 subjects were found to have an AAA. In a logistic
regression model male gender, age and duplex-verified arterial stenosis were
independently associated with AAA (odds ratio 3.2, 2.0/20 years and 2.0,
respectively, p  0.001). In men 60 years the AAA prevalence was 0.9%
(95% confidence interval 0.2–1.6%) when arterial stenosis was absent and
1.5% (0.0–3.2%) when present. In men 60 years the AAA prevalence was
4.0% (3.0–5.1%) when no arterial stenosis was found and 7.3% (5.7–8.9%)
when found. The corresponding prevalences in women were 0%, 0%, 1.2%
(0.5–1.8%), and 3.1% (1.9–4.3%), respectively.
Conclusions: Men 60 years referred for arterial examination have a
significant risk of having an AAA while only women65 years with a duplex
verified arterial stenosis have a sufficient risk of having an AAA. Studies to
evaluate the benefit of selective high-risk screening are warranted.
EVAR of Aortoiliac Aneurysms with Branched Stent-grafts
Dias N.V., Resch T.A., Sonesson B., Ivancev K., Malina M. Eur J Vasc
Endovasc Surg 2008;35:677-84.
Introduction: Branched iliac stent-grafts (bSG) have recently been
developed in order to preserve internal iliac artery (IIA) flow in patients with
aneurysmal or short common iliac arteries. The aim of this study is to
evaluate a single-center experience with bSG for the IIA.
Methods: Twenty-two male patients (70 (IQR 65–79) years old)
underwent EVARwith 23 bSG (1 bilateral repair) between September 2002
and August 2007. Median AAA diameter was 52 (37–60) mm while
common iliac diameter on the side of the bSG was 34 (27–41) mm. Two
in-house modified Zenith SG and subsequently 21 commercially available
bSG (18 Zenith Iliac Side and 3 Helical Branches) were used. Follow-up
(FU) included CT at one month and yearly thereafter. Data was prospec-
tively entered in a database.
Results: Primary technical success was 91% (21 bSG). Median FU
duration was 20 (8–31) months. One patient (5 %) died after discharge from
acute myocardial infarction on day 13. Another patient died 30months after
EVAR of an unrelated cause. The overall bSG patency was 74% due to 6
branch occlusions (2 intraoperative and 4 late). All patients with patent bSG
were asymptomatic. Three occlusions were asymptomatic findings on CT,
while the other three developed claudication (two patients with contralateral
IIA occlusion and one with simultaneous occlusion of the external iliac).
One patient (5%) developed an asymptomatic type III endoleak at 1 month
and was successfully treated with a bridging SG. Overall, four patients (18%)
required reinterventions (1 bilateral stenting of the external iliac arteries, 1
external and 1 internal SG extensions and 1 femoro-femoral cross-over
bypass). Nine out of 16 patients (56%) with CT-FU  1 year had shrinking
aneurysms. There were no postoperative aneurysm expansions.
Conclusions: EVAR of aortoiliac aneurysms with IIA bSG is a good
alternative to occlusion of the IIA in patients with challenging distal anatomy.
Management of Hypertension in Peripheral Arterial Disease: Does the
Choice of Drugs Matter?
Singer D.R.J., Kite A. Eur J Vasc Endovasc Surg 2008;35:701-08.
Cardiovascular disease and death aremajor life-threatening problems in
patients with atheromatous peripheral arterial disease (PAD). This review
focuses on management of hypertension in the context of cardiovascular risk
in patients with PAD. PAD is underdiagnosed and hypertension in PAD is
often poorly managed. Current evidence supports a low threshold for blood
pressure treatment in PAD and intensive blood pressure control to reduce
the high risk of cardiovascular disease and death in patients with PAD.
Optimal treatment targets should be 140/85 mmHg, with the lower
target of 130/80 mmHg in the presence of diabetes mellitus or chronic
renal disease. Class-specific selection of anti-hypertensive treatments in PAD
should be based on caution in relation to co-existing renovascular disease
and indications and contraindications based on other significant co-morbid-
ity. There is a pressing need for primary end-point studies targeted specifi-
cally at patients with PAD. In particular, prospective studies in PAD are
needed to obtain evidence for benefits from specific blood pressure classes of
treatment as well as the optimal blood pressure treatment target level. These
studies should consider impact in PAD of different demographic, risk factor,
and co-morbidity profiles.
1374
